Cetera Investment Advisers
BMY.RT

Cetera Investment Advisers’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Cetera Investment Advisers’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-53,082
Closed -$37K – 1746
2020
Q4 		$37K Buy
+53,082
New +$113K ﹤0.01% 1542

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Cetera Investment Advisers's BMY.RT Position: Q1 2021 in Review

Cetera Investment Advisers sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 53,082 shares — an estimated $37K sold.

Cetera Investment Advisers first reported a position in BMY.RT in Q4 2020 and held it in 1 quarter. The position peaked at $37K in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Cetera Investment Advisers reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Cetera Investment Advisers sold 53,082 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $37K.
  • Cetera Investment Advisers first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2020 and held it in 1 quarter.
  • Cetera Investment Advisers's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $37K in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Cetera Investment Advisers's 13F filing for Q1 2021, filed 17 May 2021.